Diagnostic value of novel hepatic fibrosis markers in assessing cirrhosis in patients with chronic hepatitis C.
10.3760/cma.j.cn501113-20220329-00149
- Author:
Qian KANG
1
;
Jian Xiang LIU
2
;
Ning TAN
1
;
Hong Yu CHEN
1
;
Jia Li PAN
1
;
Yi Fan HAN
1
;
Xiao Yuan XU
2
Author Information
1. Department of Infectious Diseases, Peking University First Hospital, Beijing 100034, China.
2. Department of Gastroenterology, Peking University First Hospital, Beijing 100034, China.
- Publication Type:Journal Article
- Keywords:
Chitinase-3-like protein 1;
Chronic hepatitis C;
Direct antiviral agents;
Fibrosis;
Golgi protein 73
- MeSH:
Humans;
Hepatitis C, Chronic/drug therapy*;
Antiviral Agents/therapeutic use*;
Membrane Proteins/metabolism*;
Liver Cirrhosis/diagnosis*;
Fibrosis;
Biomarkers
- From:
Chinese Journal of Hepatology
2023;31(1):56-64
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To investigate the efficacy of chitinase-3-like protein 1 (CHI3L1) and Golgi protein 73 (GP73) in the diagnosis of cirrhosis and the dynamic changes of CHI3L1 and GP73 after HCV clearance in patients with chronic hepatitis C (CHC) treated with direct-acting antiviral drugs (DAAs). The comparison of continuous variables of normal distribution were statistically analyzed by ANOVA and t-test. The comparison of continuous variables of non-normal distribution were statistically analyzed by rank sum test. The categorical variables were statistically analyzed by Fisher's exact test and χ(2) test. Correlation analysis was performed using Spearman correlation analysis. Methods: Data of 105 patients with CHC diagnosed from January 2017 to December 2019 were collected. The receiver operating characteristic curve (ROC curve) was plotted to study the efficacy of serum CHI3L1 and GP73 for the diagnosis of cirrhosis. Friedman test was used to compare CHI3L1 and GP73 change characteristics. Results: The areas under the ROC curve for CHI3L1 and GP73 in the diagnosis of cirrhosis at baseline were 0.939 and 0.839, respectively. Serum levels of CHI3L1 and GP73 in the DAAs group decreased significantly at the end of treatment compared with baseline [123.79 (60.25, 178.80) ng/ml vs. 118.20 (47.68, 151.36) ng/ml, P = 0.001; 105.73 (85.05, 130.69) ng/ml vs. 95.52 (69.52, 118.97) ng/ml, P = 0.001]. Serum CHI3L1 and GP73 in the pegylated interferon combined with ribavirin (PR) group were significantly lower at the end of 24 weeks of treatment than the baseline [89.15 (39.15, 149.74) ng/ml vs. 69.98 (20.52, 71.96) ng/ml, P < 0.05; 85.07 (60.07, 121) ng/ml vs. 54.17 (29.17, 78.65) ng/ml, P < 0.05]. Conclusion: CHI3L1 and GP73 are sensitive serological markers that can be used to monitor the fibrosis prognosis in CHC patients during treatment and after obtaining a sustained virological response. Serum CHI3L1 and GP73 levels in the DAAs group decreased earlier than those in the PR group, and the serum CHI3L1 levels in the untreated group increased compared with the baseline at about two years of follow-up.
